Abt-510 (BioDeep_00000837883)
代谢物信息卡片
化学式: C46H83N13O11 (993.6334688000001)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CCCC(C(=O)NC(C(C)CC)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC)NC(=O)C(C(C)O)NC(=O)C(C(C)CC)NC(=O)C(C(C)C)NC(=O)CNC(=O)CN(C)C(=O)C
InChI: InChI=1S/C46H83N13O11/c1-12-18-30(39(64)55-36(26(7)13-2)42(67)53-31(19-16-21-50-46(47)48)45(70)59-22-17-20-32(59)40(65)49-15-4)52-44(69)38(28(9)60)57-43(68)37(27(8)14-3)56-41(66)35(25(5)6)54-33(62)23-51-34(63)24-58(11)29(10)61/h25-28,30-32,35-38,60H,12-24H2,1-11H3,(H,49,65)(H,51,63)(H,52,69)(H,53,67)(H,54,62)(H,55,64)(H,56,66)(H,57,68)(H4,47,48,50)/t26-,27-,28+,30-,31-,32-,35-,36-,37+,38-/m0/s1
描述信息
C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor > C1971 - Angiogenesis Activator Inhibitor
同义名列表
1 个代谢物同义名
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Hope E Uronis, Stephanie M Cushman, Johanna C Bendell, Gerard C Blobe, Michael A Morse, Andrew B Nixon, Andrew Dellinger, Mark D Starr, Haiyan Li, Kellen Meadows, Jon Gockerman, Herbert Pang, Herbert I Hurwitz. A phase I study of ABT-510 plus bevacizumab in advanced solid tumors.
Cancer medicine.
2013 Jun; 2(3):316-24. doi:
10.1002/cam4.65. [PMID: 23930208] - Gerald N Audet, Daniel Fulks, Janelle C Stricker, I Mark Olfert. Chronic delivery of a thrombospondin-1 mimetic decreases skeletal muscle capillarity in mice.
PloS one.
2013; 8(2):e55953. doi:
10.1371/journal.pone.0055953. [PMID: 23405239] - M Victoria Recouvreux, M Andrea Camilletti, Daniel B Rifkin, Damasia Becu-Villalobos, Graciela Díaz-Torga. Thrombospondin-1 (TSP-1) analogs ABT-510 and ABT-898 inhibit prolactinoma growth and recover active pituitary transforming growth factor-β1 (TGF-β1).
Endocrinology.
2012 Aug; 153(8):3861-71. doi:
10.1210/en.2012-1007. [PMID: 22700773] - Scot Ebbinghaus, Maha Hussain, Nizar Tannir, Michael Gordon, Apurva A Desai, Raymond A Knight, Rod A Humerickhouse, Jiang Qian, Gary B Gordon, Robert Figlin. Phase 2 study of ABT-510 in patients with previously untreated advanced renal cell carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2007 Nov; 13(22 Pt 1):6689-95. doi:
10.1158/1078-0432.ccr-07-1477. [PMID: 18006769] - J A Gietema, R Hoekstra, F Y F L de Vos, D R A Uges, A van der Gaast, H J M Groen, W J Loos, R A Knight, R A Carr, R A Humerickhouse, F A L M Eskens. A phase I study assessing the safety and pharmacokinetics of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with gemcitabine and cisplatin in patients with solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology.
2006 Aug; 17(8):1320-7. doi:
10.1093/annonc/mdl102. [PMID: 16728485] - R Hoekstra, F Y F L de Vos, F A L M Eskens, E G E de Vries, D R A Uges, R Knight, R A Carr, R Humerickhouse, J Verweij, J A Gietema. Phase I study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with 5-fluorouracil and leucovorin: a safe combination.
European journal of cancer (Oxford, England : 1990).
2006 Mar; 42(4):467-72. doi:
10.1016/j.ejca.2005.08.040. [PMID: 16406507] - Ronald Hoekstra, Filip Y F L de Vos, Ferry A L M Eskens, Jourik A Gietema, Ate van der Gaast, Harry J M Groen, Raymond A Knight, Robert A Carr, Rod A Humerickhouse, Jaap Verweij, Elisabeth G E de Vries. Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2005 Aug; 23(22):5188-97. doi:
10.1200/jco.2005.05.013. [PMID: 16051960]